Metabolic SyndromeKREBSome-IRCNCT06360302
Plasma Biomarkers of Muscle Metabolism During Exercise to the Assessment of Insulin Resistance in CKD Dialysis Patients
A study testing Exercise test, Blood sample and Impedancemetry in people with Metabolic Syndrome and Dialysis; Complications, run by University Hospital, Montpellier at 2 sites in France.
Trial summary
This prospective, multicenter, cross-sectional, repeated-measures comparative study compared functional and biochemical response profiles to exercise between 2 groups of chronically ill patients (chronic renal failure dialysis patients and patients with metabolic syndrome) and a group of healthy subjects. Read more about this study
- Who is it for?
- Ages 40 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Metabolic Syndrome, Dialysis; Complications
- What is being tested?
- Exercise test, Blood sample and Impedancemetry
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 42 participants
- Where
- 2 sitesFrance
- Study dates
- 18 Nov 2024to 18 Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Group 1: Healthy subjects:
- Postmenopausal women aged 40 to 75 or men aged 40 to 75
- No chronic disease or treatment
- BMI <30 kg/m², or
- Fasting blood glucose < 1.10 g/dL
- Group 2: metabolic syndrome patients
Show all 16Show fewer
- Postmenopausal women aged 40 to 75 or men aged 40 to 75
- Metabolic syndrome as defined by the International Diabetes Federation (IDF 2006)5
- BMI <30 kg/m² and waist circumference >80 cm for women and >94 cm for men
- Insulin resistance defined by HOMA-IR>2.4
- Group 3: CKD dialysis patients
- Non-diabetics
- Postmenopausal women aged 40 to 75 and men aged 40 to 75
- BMI <30 kg/m².
- Chronic kidney disease patients on dialysis - stable on HD for more than 3 months
- Patients and healthy subjects will be matched on age (+/-3 years) and sex
Who cannot join
- Non-stabilized pathology incompatible with physical exercise
- Ongoing exercise retraining program
- Nutritional supplementation in the 4 weeks preceding the study (antioxidants, vitamins, etc.)
- Treatment influencing mitochondrial function (metformin, statin, etc.)
- Failure to obtain written informed consent after a period of reflection
- Subject not affiliated to a social security scheme, or not benefiting from such a scheme.
Show all 14Show fewer
- Person protected by law (under guardianship or curatorship)
- Patient deprived of liberty
- Diabetic patient
- Family dyslipidemia
- Participants who have reached the maximum amount of compensation for their participation in research projects
- Person under psychiatric care
- Person participating in another research project with an exclusion period still in progress.
- Mentally handicapped, dementia, illiterate, language barrier with inability to understand study purpose and methodology
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
FARES GOUZI, MD PhD contact
France2 sites, 2 recruiting
- Recruiting
AIDER Santé Fondation Charles Mion Montpellier, site Lapeyronie
Montpellier, 34295
Jean-Paul CRISTOL, Prof, +33(0)4 67 33 83 15, jp-cristol@chu-montpellier.fr
- Recruiting
Montpellier University Hospital
Montpellier, 34295
Farès GOUZI, MD, PhD, +33 467 335 908, f-gouzi@chu-montpellier.fr
Farès GOUZI
About this study
Official title: Contribution of Plasma Assays of Biomarkers of Muscle Metabolism During Exercise to the Assessment of Insulin Resistance in Chronic Renal Failure Patients Undergoing Hemodialysis.
This prospective, multicenter, cross-sectional, repeated-measures comparative study compared functional and biochemical response profiles to exercise between 2 groups of chronically ill patients (chronic renal failure dialysis patients and patients with metabolic syndrome) and a group of healthy subjects.
The hypothesis is that the addition of plasma metabolic intermediates associated with energy disorders linked to insulin resistance, will improve the sensitivity of the assessment of muscle oxidative metabolism abnormalities, as reported in exercise intolerant subjects.
Read more
In this way, the metabolomics approach during exercise would provide a biological and functional "signature" of insulin resistance of muscular origin, discriminating between insulin-resistant patients, healthy control subjects and dialysis patients, with an exercise metabolic profile approaching that observed in insulin-resistant patients. A better understanding of metabolic abnormalities could guide muscle rehabilitation.
Participants will be asked to perform an exercise test, with several blood samples taken at different exercise intensities.
Researchers will compare the metabolic profile of three groups: patients with chronic kidney disease, patients with metabolic syndrome and healthy subjects:
- V'O2-adjusted lactate at rest and during exercise
- The combination of exercise energy metabolism intermediates reflecting insulin resistance among Krebs cycle cofactors/substrates, ß-oxidation cofactors/substrates, amino acids
Read the detailed description
Chronic renal failure (or CKD) is a chronic disease requiring end-stage replacement of renal function by extra-renal purification via hemodialysis (HD). CKD patients on dialysis suffer from numerous severe co-morbidities, limiting the possibility of renal transplantation.
Metabolic impairments are numerous and complex: dyslipidemia, phospho-calcium disorders, hormonal and nutritional disturbances.
In these patients, the onset of insulin resistance is virtually systematic, but its assessment remains a challenge. In fact, the classic screening method known as HOMA-IR, using simultaneous measurement of insulin and plasma glucose levels, is greatly affected by dialysis and the timing of its implementation. The reference method known as the hyperinsulinemic-euglycemic clamp is difficult to perform in HD patients.
While insulin resistance is a condition that can be reversed by physical activity in chronic pathologies, the absence of a validated assessment method for CKD in HD represents a missed opportunity for prevention in CKD, at a time when muscle rehabilitation programs are developing in CKD.
Moreover, insulin resistance is associated with skeletal striated muscle dysfunction in CKD patients, and constitutes another major comorbidity in these patients, as skeletal striated muscle is the main tissue utilizing glucose in response to insulin. The research team has shown that muscular dysfunctions associating reduced muscle strength and/or muscular atrophy are a morbi-mortality factor in dialysis patients. Finally, molecular abnormalities associate a switch of muscle fibers towards glycolytic fibers and mitochondrial abnormalities strongly suggesting an energy dysfunction.
In a preliminary study, the research team were able to demonstrate in dialysis patients an alteration in energy metabolism, comparable to a loss of "metabolic flexibility", mimicking that observed in insulin-resistant patients without renal dysfunction. A better understanding of the components of energy anomalies and insulin resistance could guide muscle rehabilitation protocols and prevent complications associated with insulin resistance.
Currently, the only valid, non-invasive method used in clinical practice to demonstrate impairment of muscular oxidative metabolism is the measurement of carbohydrate/lipid utilization rate during an exercise test. This "metabolic stress test" makes it possible to determine the point of maximum lipid utilization (LIPOXMAX), the current reference marker of muscle metabolism during exercise.
Nevertheless, LIPOXMAX alone cannot provide an understanding of underlying metabolic abnormalities in energy pathways, and the assay of different muscle metabolites released into plasma during exercise (and their combination) has recently emerged as a specific and early assessment of insulin resistance.
In particular, parameters such as lactate or pyruvate measured in plasma at rest have been positively correlated with the HOMA-IR index and associated with an increased risk of developing type 2 diabetes. During exercise (metabolic stress test), lactate levels in insulin-resistant patients differ from those in healthy controls.
In view of the abnormalities of oxidative muscle metabolism in CKD and insulin-resistant patients, the measurement of lactate at rest and during exercise, adjusted for V'O2, could reveal a profile enabling discrimination of CKD and insulin-resistant patients from healthy control subjects.
With the addition of plasma metabolic intermediates associated with energy disorders linked to insulin resistance, The investigators hypothesize that their measurement during exercise will improve the sensitivity of the assessment of muscle oxidative metabolism abnormalities, as reported in exercise-intolerant subjects.
The metabolomics approach during exercise would provide a biological and functional "signature" of muscle-induced insulin resistance in haemodialysis patients. A better understanding of metabolic abnormalities could guide muscle rehabilitation.
This prospective, cross-sectional, repeated-measures comparative study comparing functional and biochemical response profiles to exercise between 2 groups of chronically ill patients and a group of healthy subjects.
This comparison of the metabolisms of the 3 groups is analyzed using repeated plasma sampling at different effort intensities.
- Plasma lactate adjusted to V'O2 (ratio) at rest and during exercise.
- V'O2-adjusted metabolic profile at rest and during exercise through a combination of exercise energy metabolism intermediates based on candidate metabolites with a significant correlation coefficient >0.7 compared to LIPOXmax and/or HOMA-IR, among the following:
- Krebs cycle cofactors/substrates (lactate, pyruvate, malate, citrate, succinate, fumarate and alpha-cetoglutarate)
- ß-oxidation cofactors/substrates (free fatty acids, acyl-carnitine profile, beta-hydroxybutyrate, acetoacetate)
- Amino acid profile
- Acyl carnitine profile
- Conditions
- Metabolic Syndrome, Dialysis; Complications
- Being tested
- Exercise test, Blood sample, Impedancemetry
- Keywords
- exercise test, Citric Acid Cycle, metabolomic
- Medical subject headings
- Metabolic Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Exercise testDiagnostic test
"Metabolic" effort test on cycloergometer with gas measurement. Gas exchanges (V'O2 and V'CO2) will be measured cycle-by-cycle using a gas analyzer connected to a flow meter Measurements will be taken every 6 minutes, at rest and during exercise on a cycloergometer, in five 6-minute increments, corresponding to intensities of 0% (rest), 20%, 30%, 40%, 50 and 60% of the subject's estimated maximum power, for a total duration of around 45 minutes.
Blood sampleDiagnostic test
A catheter will be placed in a forearm vein to take blood samples at rest and at the end of the 5-stage stress test.
Sampling times synchronized with stress test measurements
ImpedancemetryDiagnostic test
measurement of anthropometric data (weight, height, waist circumference). impedancemetry will enable body composition to be analyzed by placing surface electrodes on the body. The participant will lie on an examination table and must remain at rest for 5 minutes.
| Study group | Role | What they receive |
|---|---|---|
| Healthy volunters | Active comparator | Voluntary participants with no chronic diseases aged 40 to 75 wishing to take part in the study and benefit from an exercise test. Receives: Diagnostic Test: Exercise test; Diagnostic Test: Blood sample; Diagnostic Test: Impedancemetry |
| Metabolic syndrome patients | Active comparator | Patients aged 40 to 75 with metabolic syndrome undergoing functional assessment in the physiology department. Receives: Diagnostic Test: Exercise test; Diagnostic Test: Blood sample; Diagnostic Test: Impedancemetry |
| CKD dialysis patients | Experimental | Chronic renal failure patients on dialysis, stable hemodialysis for more than 3 months Receives: Diagnostic Test: Exercise test; Diagnostic Test: Blood sample; Diagnostic Test: Impedancemetry |
What is being measured
The primary outcome is the main question the study is designed to answer.
Compare V'O2-adjusted plasma lactate profile at rest and during exercise (metabolic stress test), between chronic renal failure patients, patients with metabolic syndrome and healthy subjects.
Measurements will be taken every 6 minutes, at rest and during exercise on a cycloergometer, corresponding to intensities of 0% (rest) 20%, 30%, 40%, 50 and 60% of the subject's estimated maximum power.
The gas exchange measurement (V'O2 and V'CO2 (milliliter per minute mL/min)) will be carried out cycle-by-cycle using a gas analyzer connected to a flow meter.
The intensity corresponding to the rate of maximum lipid oxidation will be defined as LIPOXMAX, and will be expressed in Watts (W), and as a % of theoretical VO2max.
Carbohydrate (G) and lipid (L) oxidation rates will be calculated as follows:
- G (mg/min) = 4.585 VCO2 - 3.2255 VO2
- L (mg/min) = 1.6946 VO2 - 1.7012 VCO2
Blood sampling at various levels on a peripheral venous catheter synchronized with stress test measurements.
A comparison will be made on the basis of an analysis of variance by ANOVA one way after verification of the conditions of application or a rank test by analysis via Kruskal-Wallis.
Measured: Baseline (rest), 6, 12, 18, 24, 30 minutes
Secondary outcomes (5)
Compare between the 3 groups their metabolic profile (Krebs cycle cofactors/substrates) adjusted to V'O2 at rest and during exercise.
"Metabolic" Exercice test on a cycloergometer with gas measurement and peripheral venous sampling at various intensities.
HOMA-IR score (Homeostatic model assessment of insulin resistance) is calculated using simultaneous measurement of insulin and plasma glucose levels, a score above 2.4 is diagnostic of insulin resistance.
A combination of exercise energy metabolism intermediates based on candidate metabolites with a significant correlation coefficient >0.7 compared to LIPOXmax and/or HOMA-IR, from among the following Krebs cycle cofactors/substrates : lactate, pyruvate, malate, citrate, succinate, fumarate and alpha-cetoglutarate
Correlations will be characterized by Pearson's correlation test (correlation considered significant for coefficients >0.7).
Logistic regression analysis will be used to characterize insulin resistance in the different groups on the basis of the data collected.
Measured: Baseline (rest), 6, 12, 18, 24, 30 minutes
Compare between the 3 groups their metabolic profile (ß-oxidation cofactors/substrates) adjusted to V'O2 at rest and during exercise.
"Metabolic" Exercise test on a cycloergometer with gas measurement and peripheral venous sampling at various intensities.
HOMA-IR score (Homeostatic model assessment of insulin resistance) is calculated using simultaneous measurement of insulin and plasma glucose levels, a score above 2.4 is diagnostic of insulin resistance.
A combination of exercise energy metabolism intermediates based on candidate metabolites with a significant correlation coefficient >0.7 compared to LIPOXmax and/or HOMA-IR, from among the following ß-oxidation cofactors/substrates : free fatty acids, acyl-carnitine profile, beta-hydroxybutyrate, acetoacetate
Correlations will be characterized by Pearson's correlation test (correlation considered significant for coefficients >0.7).
Logistic regression analysis will be used to characterize insulin resistance in the different groups on the basis of the data collected.
Measured: Baseline (rest), 6, 12, 18, 24, 30 minutes
Compare between the 3 groups their metabolic profile (amino acids) adjusted to V'O2 at rest and during exercise.
"Metabolic" Exercise test on a cycloergometer with gas measurement and peripheral venous sampling at various intensities.
HOMA-IR score (Homeostatic model assessment of insulin resistance) is calculated using simultaneous measurement of insulin and plasma glucose levels, a score above 2.4 is diagnostic of insulin resistance.
A combination of exercise energy metabolism intermediates based on candidate metabolites with a significant correlation coefficient >0.7 compared to LIPOXmax and/or HOMA-IR, from among the following amino acids.
Correlations will be characterized by Pearson's correlation test (correlation considered significant for coefficients >0.7).
Logistic regression analysis will be used to characterize insulin resistance in the different groups on the basis of the data collected.
Measured: Baseline (rest), 6, 12, 18, 24, 30 minutes
Compare between the 3 groups their metabolic profile (acyl-carnitine profiles) adjusted to V'O2 at rest and during exercise.
"Metabolic" Exercise test on a cycloergometer with gas measurement and peripheral venous sampling at various intensities.
HOMA-IR score (Homeostatic model assessment of insulin resistance) is calculated using simultaneous measurement of insulin and plasma glucose levels, a score above 2.4 is diagnostic of insulin resistance.
A combination of exercise energy metabolism intermediates based on candidate metabolites with a significant correlation coefficient >0.7 compared to LIPOXmax and/or HOMA-IR, from among the following acyl-carnitine profiles
Correlations will be characterized by Pearson's correlation test (correlation considered significant for coefficients >0.7).
Logistic regression analysis will be used to characterize insulin resistance in the different groups on the basis of the data collected.
Measured: Baseline (rest), 6, 12, 18, 24, 30 minutes
Anthropometry Comparison between the 3 groups
calculation of BMI with the Measurement of weight (in kilograms Kg) and height (in centimetres cm).
Measured: Baseline (rest)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Apr 2024
- Study start18 Nov 2024
- Primary completion18 Nov 2026 (estimated)
- Study completion18 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Metabolic SyndromeStudies of the same condition, open and under way.
- More trials run by University Hospital, MontpellierThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Cross-sectional comparative study with repeated measures
- Masking
- None (open label)
- Enrolment
- 42 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Montpellier
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- GRILLET Pierre-Edouard, Pharma D. PhD, Study director, University Hospital, Montpellier
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06360302
- Sponsor's protocol ID
- RECHMPL22_0505
- Acronym
- KREBSome-IRC
- Status last verified
- Nov 2024
- First submitted
- 8 Apr 2024
- Last updated
- 26 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Contribution of Plasma Assays of Biomarkers of Muscle Metabolism During Exercise to the Assessment of Insulin Resistance in Chronic Renal Failure Patients Undergoing Hemodialysis.
- ClinicalTrials.gov ID
- NCT06360302
- Acronym / sponsor ID
- KREBSome-IRC / RECHMPL22_0505
- Conditions
- Metabolic Syndrome, Dialysis; Complications
- Keywords
- exercise test, Citric Acid Cycle, metabolomic
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 42 participants (estimated)
- Lead sponsor
- University Hospital, MontpellierUniversity, hospital or other
- Study start
- 18 Nov 2024 (actual)
- Primary completion
- 18 Nov 2026 (estimated)
- Study completion
- 18 Nov 2026 (estimated)
- First posted
- 11 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective, multicenter, cross-sectional, repeated-measures comparative study compared functional and biochemical response profiles to exercise between 2 groups of chronically ill patients (chronic renal failure dialysis patients and patients with metabolic syndrome) and a group of healthy subjects.
The hypothesis is that the addition of plasma metabolic intermediates associated with energy disorders linked to insulin resistance, will improve the sensitivity of the assessment of muscle oxidative metabolism abnormalities, as reported in exercise intolerant subjects.
In this way, the metabolomics approach during exercise would provide a biological and functional "signature" of insulin resistance of muscular origin, discriminating between insulin-resistant patients, healthy control subjects and dialysis patients, with an exercise metabolic profile approaching that observed in insulin-resistant patients. A better understanding of metabolic abnormalities could guide muscle rehabilitation.
Participants will be asked to perform an exercise test, with several blood samples taken at different exercise intensities.
Researchers will compare the metabolic profile of three groups: patients with chronic kidney disease, patients with metabolic syndrome and healthy subjects:
- V'O2-adjusted lactate at rest and during exercise
- The combination of exercise energy metabolism intermediates reflecting insulin resistance among Krebs cycle cofactors/substrates, ß-oxidation cofactors/substrates, amino acids
Detailed description
Chronic renal failure (or CKD) is a chronic disease requiring end-stage replacement of renal function by extra-renal purification via hemodialysis (HD). CKD patients on dialysis suffer from numerous severe co-morbidities, limiting the possibility of renal transplantation.
Metabolic impairments are numerous and complex: dyslipidemia, phospho-calcium disorders, hormonal and nutritional disturbances.
In these patients, the onset of insulin resistance is virtually systematic, but its assessment remains a challenge. In fact, the classic screening method known as HOMA-IR, using simultaneous measurement of insulin and plasma glucose levels, is greatly affected by dialysis and the timing of its implementation. The reference method known as the hyperinsulinemic-euglycemic clamp is difficult to perform in HD patients.
While insulin resistance is a condition that can be reversed by physical activity in chronic pathologies, the absence of a validated assessment method for CKD in HD represents a missed opportunity for prevention in CKD, at a time when muscle rehabilitation programs are developing in CKD.
Moreover, insulin resistance is associated with skeletal striated muscle dysfunction in CKD patients, and constitutes another major comorbidity in these patients, as skeletal striated muscle is the main tissue utilizing glucose in response to insulin. The research team has shown that muscular dysfunctions associating reduced muscle strength and/or muscular atrophy are a morbi-mortality factor in dialysis patients. Finally, molecular abnormalities associate a switch of muscle fibers towards glycolytic fibers and mitochondrial abnormalities strongly suggesting an energy dysfunction.
In a preliminary study, the research team were able to demonstrate in dialysis patients an alteration in energy metabolism, comparable to a loss of "metabolic flexibility", mimicking that observed in insulin-resistant patients without renal dysfunction. A better understanding of the components of energy anomalies and insulin resistance could guide muscle rehabilitation protocols and prevent complications associated with insulin resistance.
Currently, the only valid, non-invasive method used in clinical practice to demonstrate impairment of muscular oxidative metabolism is the measurement of carbohydrate/lipid utilization rate during an exercise test. This "metabolic stress test" makes it possible to determine the point of maximum lipid utilization (LIPOXMAX), the current reference marker of muscle metabolism during exercise.
Nevertheless, LIPOXMAX alone cannot provide an understanding of underlying metabolic abnormalities in energy pathways, and the assay of different muscle metabolites released into plasma during exercise (and their combination) has recently emerged as a specific and early assessment of insulin resistance.
In particular, parameters such as lactate or pyruvate measured in plasma at rest have been positively correlated with the HOMA-IR index and associated with an increased risk of developing type 2 diabetes. During exercise (metabolic stress test), lactate levels in insulin-resistant patients differ from those in healthy controls.
In view of the abnormalities of oxidative muscle metabolism in CKD and insulin-resistant patients, the measurement of lactate at rest and during exercise, adjusted for V'O2, could reveal a profile enabling discrimination of CKD and insulin-resistant patients from healthy control subjects.
With the addition of plasma metabolic intermediates associated with energy disorders linked to insulin resistance, The investigators hypothesize that their measurement during exercise will improve the sensitivity of the assessment of muscle oxidative metabolism abnormalities, as reported in exercise-intolerant subjects.
The metabolomics approach during exercise would provide a biological and functional "signature" of muscle-induced insulin resistance in haemodialysis patients. A better understanding of metabolic abnormalities could guide muscle rehabilitation.
This prospective, cross-sectional, repeated-measures comparative study comparing functional and biochemical response profiles to exercise between 2 groups of chronically ill patients and a group of healthy subjects.
This comparison of the metabolisms of the 3 groups is analyzed using repeated plasma sampling at different effort intensities.
- Plasma lactate adjusted to V'O2 (ratio) at rest and during exercise.
- V'O2-adjusted metabolic profile at rest and during exercise through a combination of exercise energy metabolism intermediates based on candidate metabolites with a significant correlation coefficient >0.7 compared to LIPOXmax and/or HOMA-IR, among the following:
- Krebs cycle cofactors/substrates (lactate, pyruvate, malate, citrate, succinate, fumarate and alpha-cetoglutarate)
- ß-oxidation cofactors/substrates (free fatty acids, acyl-carnitine profile, beta-hydroxybutyrate, acetoacetate)
- Amino acid profile
- Acyl carnitine profile
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- Cross-sectional comparative study with repeated measures
| Arm | Type | Receives |
|---|---|---|
| Healthy volunters | Active comparator | Diagnostic Test: Exercise test, Diagnostic Test: Blood sample, Diagnostic Test: ImpedancemetryVoluntary participants with no chronic diseases aged 40 to 75 wishing to take part in the study and benefit from an exercise test. |
| Metabolic syndrome patients | Active comparator | Diagnostic Test: Exercise test, Diagnostic Test: Blood sample, Diagnostic Test: ImpedancemetryPatients aged 40 to 75 with metabolic syndrome undergoing functional assessment in the physiology department. |
| CKD dialysis patients | Experimental | Diagnostic Test: Exercise test, Diagnostic Test: Blood sample, Diagnostic Test: ImpedancemetryChronic renal failure patients on dialysis, stable hemodialysis for more than 3 months |
Who may qualify
- Ages
- 40 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (16 listed)
- Postmenopausal women aged 40 to 75 or men aged 40 to 75
- No chronic disease or treatment
- BMI <30 kg/m², or
- Fasting blood glucose < 1.10 g/dL
- Group 2: metabolic syndrome patients
Key exclusion criteria (14 listed)
- Non-stabilized pathology incompatible with physical exercise
- Ongoing exercise retraining program
- Nutritional supplementation in the 4 weeks preceding the study (antioxidants, vitamins, etc.)
- Treatment influencing mitochondrial function (metformin, statin, etc.)
- Failure to obtain written informed consent after a period of reflection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Exercise test"Metabolic" effort test on cycloergometer with gas measurement. Gas exchanges (V'O2 and V'CO2) will be measured cycle-by-cycle using a gas analyzer connected to a flow meter Measurements will be taken every 6 minutes, at rest and during exercise on a cycloergometer, in five 6-minute increments, corresponding to intensities of 0% (rest), 20%, 30%, 40%, 50 and 60% of the subject's estimated maximum power, for a total duration of around 45 minutes. | Diagnostic test | CKD dialysis patients, Healthy volunters, Metabolic syndrome patients |
| Blood sampleA catheter will be placed in a forearm vein to take blood samples at rest and at the end of the 5-stage stress test. Sampling times synchronized with stress test measurements | Diagnostic test | CKD dialysis patients, Healthy volunters, Metabolic syndrome patients |
| Impedancemetrymeasurement of anthropometric data (weight, height, waist circumference). impedancemetry will enable body composition to be analyzed by placing surface electrodes on the body. The participant will lie on an examination table and must remain at rest for 5 minutes. | Diagnostic test | CKD dialysis patients, Healthy volunters, Metabolic syndrome patients |
Primary outcome
Compare V'O2-adjusted plasma lactate profile at rest and during exercise (metabolic stress test), between chronic renal failure patients, patients with metabolic syndrome and healthy subjects.
Time frame: Baseline (rest), 6, 12, 18, 24, 30 minutes
Measurements will be taken every 6 minutes, at rest and during exercise on a cycloergometer, corresponding to intensities of 0% (rest) 20%, 30%, 40%, 50 and 60% of the subject's estimated maximum power. The gas exchange measurement (V'O2 and V'CO2 (milliliter per minute mL/min)) will be carried out cycle-by-cycle using a gas analyzer connected to a flow meter. The intensity corresponding to the rate of maximum lipid oxidation will be defined as LIPOXMAX, and will be expressed in Watts (W), and as a % of theoretical VO2max. Carbohydrate (G) and lipid (L) oxidation rates will be calculated as follows: * G (mg/min) = 4.585 VCO2 - 3.2255 VO2 * L (mg/min) = 1.6946 VO2 - 1.7012 VCO2 Blood sampling at various levels on a peripheral venous catheter synchronized with stress test measurements. A comparison will be made on the basis of an analysis of variance by ANOVA one way after verification of the conditions of application or a rank test by analysis via Kruskal-Wallis.
5 secondary outcomes
Compare between the 3 groups their metabolic profile (Krebs cycle cofactors/substrates) adjusted to V'O2 at rest and during exercise.
Time frame: Baseline (rest), 6, 12, 18, 24, 30 minutes
Compare between the 3 groups their metabolic profile (ß-oxidation cofactors/substrates) adjusted to V'O2 at rest and during exercise.
Time frame: Baseline (rest), 6, 12, 18, 24, 30 minutes
Compare between the 3 groups their metabolic profile (amino acids) adjusted to V'O2 at rest and during exercise.
Time frame: Baseline (rest), 6, 12, 18, 24, 30 minutes
Compare between the 3 groups their metabolic profile (acyl-carnitine profiles) adjusted to V'O2 at rest and during exercise.
Time frame: Baseline (rest), 6, 12, 18, 24, 30 minutes
Anthropometry Comparison between the 3 groups
Time frame: Baseline (rest)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Nov 2024.
- Individual participant dataSharing planned: No
Related trials for Metabolic Syndrome
RecruitingObservational study
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Fanconi Anemia, Inherited Bone Marrow Failure Syndrome
Not yet recruitingPhase 2
Osilodrostat for Glycemic Control in Mild Autonomous Cortisol Secretion (MACS) With Difficult-To-Control Type 2 Diabetes - A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
Mild Autonomous Cortisol Secretion (MACS), Diabetes Mellitus (Type 2)
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
Not yet recruitingObservational study
Clinical Genetics Branch Eligibility Screening Survey
Melanoma, Li-Fraumeni Syndrome
Not yet recruitingPhase 2
Effects of Meal Macronutrients on Postprandial Lipids
Nephrotic Syndrome, Lipodystrophy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
FARES GOUZI, MD PhD contact
GRILLET Pierre-Edouard, Pharma D. PhD study director
University Hospital, Montpellier
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Exercise test, Blood sample and Impedancemetry in people with Metabolic Syndrome and Dialysis; Complications, run by University Hospital, Montpellier at 2 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact GRILLET Pierre-Edouard, Pharma D. PhD (04 67 33 63 81 ext. +33, pe-grillet@chu-montpellier.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compare V'O2-adjusted plasma lactate profile at rest and during exercise (metabolic stress test), between chronic renal failure patients, patients with metabolic syndrome and healthy subjects. (time frame: Baseline (rest), 6, 12, 18, 24, 30 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Nov 2024.